Cipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company aims to improve top line growth in Europe and expand margins in South Africa. It will focus on commercial execution, resolving USFDA observations, and growing private and select tender business. Derisking top launches and resolving regulatory issues at manufacturing plants are top priorities.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.